Why the study?
Does intermittent intravenous outpatient administration of levosimendan reduce NT-proBNP, worsening of HRQoL, and heart failure hospitalizations in ambulatory patients with advanced systolic heart failure?
Population
Ambulatory patients with advanced systolic heart failure
Design
RCT, Randomised
Authors
Loading...
May support intermittent levosimendan in advanced systolic HF; extends equivocal prior data but requires larger confirmatory RCTs.
Does intermittent intravenous outpatient administration of levosimendan reduce NT-proBNP, worsening of HRQoL, and heart failure hospitalizations in ambulatory patients with advanced systolic heart failure?
In a small pilot study, intermittent outpatient intravenous levosimendan showed potential benefits in reducing NT-proBNP, preventing HRQoL deterioration, and reducing hospitalizations in advanced systolic heart failure.
Comín‐Colet et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: